CIK 0001395937
- Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 320162505
- Phone
- +1 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- 4 Open-market sale Chief Financial Officer sold 577 shares at $22.31 ($12,873)
- 4 Planned sale Director sold 52,855 shares at $21.18 ($1,119,421)
- 4 Planned sale Director sold 52,855 shares at $21.41 ($1,131,478)
- 4 Planned sale Director sold 52,855 shares at $19.53 ($1,032,237)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President, Head of R&D sold 52,854 shares at $22.53 ($1,190,674)
- 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.84 ($646,093)
- 4 Open-market sale Chief Executive Officer sold 5,959 shares at $27.64 ($164,697)
- 4 Open-market sale President, Head of R&D sold 52,854 shares at $26.83 ($1,417,909)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 69 shares at $28.43 ($1,962)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 32,000 shares (grant or award)
- 4 Grant or award Director acquired 16,000 shares (grant or award)
- 4 Grant or award Director acquired 16,000 shares (grant or award)
- 4 Grant or award Director acquired 16,000 shares (grant or award)
Page 4 of 13 · 259 filings